Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Arrhythmias

  Free Subscription


Articles published in Ann Intern Med

Retrieve available abstracts of 64 articles:
HTML format



Single Articles


    July 2021
  1. KIM DH, Pawar A, Gagne JJ, Bessette LG, et al
    Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation : A Cohort Study.
    Ann Intern Med. 2021 Jul 20. doi: 10.7326/M20-7141.
    PubMed     Abstract available


    April 2021
  2. GUE YX, Lip GYH
    In patients with AF and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin for time to clinical events.
    Ann Intern Med. 2021;174:JC43.
    PubMed     Abstract available


    March 2021
  3. DAWWAS GK, Dietrich E, Cuker A, Barnes GD, et al
    Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study.
    Ann Intern Med. 2021 Mar 30. doi: 10.7326/M20-6194.
    PubMed     Abstract available


    January 2021
  4. STEINBERG DI
    In older patients with AF, low-dose edoxaban reduced stroke or systemic embolism without increasing major bleeding.
    Ann Intern Med. 2021;174:JC5.
    PubMed     Abstract available


  5. SANTULLI G
    In patients with early AF and CV conditions, early rhythm-control therapy vs. usual care reduced CV events at 5 years.
    Ann Intern Med. 2021;174:JC6.
    PubMed     Abstract available


    September 2020
  6. MERLI GJ, Weitz HH
    Web Exclusive. Annals Consult Guys - Atrial Fibrillation on the Run?
    Ann Intern Med. 2020;173:CG1.
    PubMed    


  7. HOFFER EP
    In AF with recent ACS or PCI, apixaban improved 30-day outcomes vs. VKAs; aspirin effects varied vs. placebo.
    Ann Intern Med. 2020;173:JC29.
    PubMed     Abstract available


    July 2020
  8. PACIULLO F, Costa C, Gresele P
    Rivaroxaban Plasma Levels and Levetiracetam: A Case Report.
    Ann Intern Med. 2020;173:71-72.
    PubMed    


    May 2020
  9. LAU WCY, Cheung CL, Man KKC, Chan EW, et al
    Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation.
    Ann Intern Med. 2020 May 19. doi: 10.7326/M19-3671.
    PubMed     Abstract available


  10. GORE M, Nagarajan V
    In adults with AF who regularly drink alcohol, a 6-month abstinence intervention reduced AF recurrence and burden.
    Ann Intern Med. 2020;172:JC53.
    PubMed     Abstract available


    April 2020
  11. MERLI GJ, Weitz HH
    Web Exclusive. Annals Consult Guys - What's the Score? Atrial Fibrillation and CHA2DS2-VASc.
    Ann Intern Med. 2020;172:CG1.
    PubMed    


    March 2020
  12. SAHA BK, Modi A, Beegle S
    Asthma From Allergy to Titanium in a Cardiac Pacemaker.
    Ann Intern Med. 2020 Mar 31. pii: 2763875. doi: 10.7326/L19-0647.
    PubMed    



  13. Correction: Should This Patient Be Screened for Atrial Fibrillation?
    Ann Intern Med. 2020;172:443.
    PubMed    


  14. KHAN SU, Osman M, Khan MU, Khan MS, et al
    Dual Versus Triple Therapy for Atrial Fibrillation After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.
    Ann Intern Med. 2020 Mar 17. pii: 2763089. doi: 10.7326/M19-3763.
    PubMed     Abstract available


  15. DOHERTY JU
    Combined Antiplatelet and Anticoagulant Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Navigating Between Scylla and Charybdis.
    Ann Intern Med. 2020 Mar 17. pii: 2763091. doi: 10.7326/M20-0572.
    PubMed    


  16. DUNN A
    In AF, DOACs were linked to lower risk for osteoporotic fractures at 2 years compared with VKAs.
    Ann Intern Med. 2020;172:JC35.
    PubMed    


  17. DUNN A
    In AF, DOACs were linked to lower risk for clinical fracture at 17 months compared with warfarin.
    Ann Intern Med. 2020;172:JC34.
    PubMed    


  18. FRALICK M, Colacci M, Schneeweiss S, Huybrechts KF, et al
    Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice: A Cohort Study.
    Ann Intern Med. 2020 Mar 10. pii: 2762724. doi: 10.7326/M19-2522.
    PubMed     Abstract available



  19. Effectiveness and Safety of Apixaban Versus Rivaroxaban for Patients With Atrial Fibrillation.
    Ann Intern Med. 2020 Mar 10. pii: 2762725. doi: 10.7326/P20-0003.
    PubMed    


    February 2020
  20. MARX GE, Leikauskas J, Lindstrom K, Mann E, et al
    Fatal Lyme Carditis in New England: Two Case Reports.
    Ann Intern Med. 2020;172:222-224.
    PubMed    


    January 2020
  21. SANTULLI G
    In AF and stable CAD, rivaroxaban reduced cardiovascular events and mortality more than rivaroxaban plus an antiplatelet.
    Ann Intern Med. 2020;172:JC6.
    PubMed    


    December 2019
  22. GUMPRECHT J, Lip GYH
    In older patients with AF, antiarrhythmic drugs were linked to fall-related injuries and syncope vs rate-lowering drugs.
    Ann Intern Med. 2019;171:JC71.
    PubMed    


  23. BURNS RB, Zimetbaum P, Lubitz SA, Smetana GW, et al
    Should This Patient Be Screened for Atrial Fibrillation?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Ann Intern Med. 2019;171:828-836.
    PubMed     Abstract available


    October 2019
  24. BATES ER
    In patients with suspected AMI and LBBB, algorithms based on ECG and troponin data were tested to rule MI in or out.
    Ann Intern Med. 2019;171:JC47.
    PubMed    


  25. BATES ER
    In suspected MI without ST elevation, a risk tool including hs-cTnI or hs-cTnT predicted diagnosis and 30-d outcomes.
    Ann Intern Med. 2019;171:JC46.
    PubMed    


  26. CENTOR RM, Reddy V
    Web Exclusive. Annals On Call - Ablating Atrial Fibrillation in Patients With Heart Failure.
    Ann Intern Med. 2019;171:OC1.
    PubMed    


    July 2019
  27. MERLI GJ, Weitz HH
    Web Exclusive. Annals Consult Guys - New Left Bundle Branch Block: Should This Block Surgery?
    Ann Intern Med. 2019;171:CG1.
    PubMed    


  28. SANTULLI G
    Catheter ablation improved quality of life more than drug therapy at 1 y in symptomatic atrial fibrillation.
    Ann Intern Med. 2019;171:JC10.
    PubMed    


  29. SANTULLI G
    Catheter ablation improved quality of life more than drug therapy at 1 y in symptomatic atrial fibrillation.
    Ann Intern Med. 2019;171:JC9.
    PubMed    


  30. SANTULLI G
    Catheter ablation did not reduce CV events and mortality more than drug therapy in symptomatic AF.
    Ann Intern Med. 2019;171:JC8.
    PubMed    


  31. HA JT, Neuen BL, Cheng LP, Jun M, et al
    Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis.
    Ann Intern Med. 2019 Jul 16. pii: 2738158. doi: 10.7326/M19-0087.
    PubMed     Abstract available


  32. TURAGAM MK, Garg J, Sartori S, Dukkipati SR, et al
    Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure.
    Ann Intern Med. 2019;171:76-77.
    PubMed    


  33. MCINTYRE WF, Whitlock RP, Belley-Cote EP
    Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure.
    Ann Intern Med. 2019;171:76.
    PubMed    


    June 2019
  34. KEARON C
    In AF, ABC scores predicted stroke or major bleeding better than CHA2DS2-VASc and HAS-BLED scores, respectively.
    Ann Intern Med. 2019;170:JC71.
    PubMed    


  35. SHAH SJ, Singer DE
    Stroke Rate Variation and Anticoagulation Benefit in Atrial Fibrillation.
    Ann Intern Med. 2019;170:818-819.
    PubMed    


  36. JOOSTEN LPT, van Doorn S, Rutten FH, Geersing GJ, et al
    Stroke Rate Variation and Anticoagulation Benefit in Atrial Fibrillation.
    Ann Intern Med. 2019;170:816-817.
    PubMed    


  37. NARDONE DA
    Stroke Rate Variation and Anticoagulation Benefit in Atrial Fibrillation.
    Ann Intern Med. 2019;170:818.
    PubMed    


  38. REIFFEL JA
    Stroke Rate Variation and Anticoagulation Benefit in Atrial Fibrillation.
    Ann Intern Med. 2019;170:818.
    PubMed    


  39. MAYER M, Alper BS, Leff L
    Stroke Rate Variation and Anticoagulation Benefit in Atrial Fibrillation.
    Ann Intern Med. 2019;170:817-818.
    PubMed    


    May 2019
  40. HELGESON SA, Mwakyanjala EJ, Parikh PP, Venkatachalam KL, et al
    Hyoscyamine for a Slow Ventricular Response During Atrial Fibrillation.
    Ann Intern Med. 2019;170:735.
    PubMed    


  41. GUPTA N
    Hyoscyamine for a Slow Ventricular Response During Atrial Fibrillation.
    Ann Intern Med. 2019;170:735.
    PubMed    



  42. Correction: Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure.
    Ann Intern Med. 2019;170:668-669.
    PubMed    


  43. LE MOIGNE E, Timsit S, Ben Salem D, Didier R, et al
    Patent Foramen Ovale and Ischemic Stroke in Patients With Pulmonary Embolism: A Prospective Cohort Study.
    Ann Intern Med. 2019 May 7. pii: 2732836. doi: 10.7326/M18-3485.
    PubMed     Abstract available


    April 2019
  44. OBEYESEKERE MN
    Review: In adults with AF and HF, AF catheter ablation vs drug therapy reduces mortality and HF hospitalizations.
    Ann Intern Med. 2019;170:JC43.
    PubMed    


    February 2019
  45. CENTOR RM, Heudebert GR
    Web Exclusive. Annals On Call - Estimating Stroke Risk in Atrial Fibrillation.
    Ann Intern Med. 2019;170:OC1.
    PubMed    


    January 2019
  46. CHAO TF, Chiang CE, Chen TJ, Lip GYH, et al
    Reassessment of Risk for Stroke During Follow-up of Patients With Atrial Fibrillation.
    Ann Intern Med. 2019 Jan 1. pii: 2720037. doi: 10.7326/M18-1177.
    PubMed    


    December 2018
  47. TURAGAM MK, Garg J, Whang W, Sartori S, et al
    Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure: A Meta-analysis of Randomized Controlled Trials.
    Ann Intern Med. 2018 Dec 25. pii: 2719811. doi: 10.7326/M18-0992.
    PubMed     Abstract available


    October 2018
  48. LOWENSTERN A, Al-Khatib SM, Sharan L, Chatterjee R, et al
    Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review.
    Ann Intern Med. 2018 Oct 30. pii: 2711395. doi: 10.7326/M18-1523.
    PubMed     Abstract available


    September 2018

  49. Stroke Rates, Atrial Fibrillation, and Drugs to Prevent Blood Clots.
    Ann Intern Med. 2018 Sep 25. pii: 2703443. doi: 10.7326/P18-0014.
    PubMed    


  50. WRIGHT JM, January CT
    Atrial Fibrillation and Anticoagulation: One Size Fits All?
    Ann Intern Med. 2018 Sep 25. pii: 2703442. doi: 10.7326/M18-2355.
    PubMed    


  51. SHAH SJ, Eckman MH, Aspberg S, Go AS, et al
    Effect of Variation in Published Stroke Rates on the Net Clinical Benefit of Anticoagulation for Atrial Fibrillation.
    Ann Intern Med. 2018 Sep 25. pii: 2703439. doi: 10.7326/M17-2762.
    PubMed     Abstract available


    August 2018

  52. Correction: Outcomes of Dabigatran and Warfarin for Atrial Fibrillation.
    Ann Intern Med. 2018;169:204.
    PubMed    


    May 2018
  53. HELGESON SA, Mwakyanjala EJ, Parikh PP, Venkatachalam KL, et al
    Hyoscyamine for a Slow Ventricular Response During Atrial Fibrillation.
    Ann Intern Med. 2018 May 15. pii: 2681482. doi: 10.7326/L18-0037.
    PubMed    


    February 2018
  54. PATEL T, Patel V
    Review: DOACs reduce intracranial hemorrhage more than warfarin in AF with CKD.
    Ann Intern Med. 2018;168:JC18.
    PubMed    


  55. KOLODZIEJCZAK M, Andreotti F, Navarese EP
    Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy.
    Ann Intern Med. 2018;168:234-235.
    PubMed    


  56. LITTMANN L
    Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy.
    Ann Intern Med. 2018;168:233.
    PubMed    


  57. SHAH R
    Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy.
    Ann Intern Med. 2018;168:233-234.
    PubMed    


    November 2017
  58. GO AS, Singer DE, Toh S, Cheetham TC, et al
    Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study.
    Ann Intern Med. 2017 Nov 14. doi: 10.7326/M16-1157.
    PubMed     Abstract available


    June 2017
  59. KOLODZIEJCZAK M, Andreotti F, Kowalewski M, Buffon A, et al
    Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy: A Systematic Review and Meta-analysis.
    Ann Intern Med. 2017 Jun 27. doi: 10.7326/M17-0120.
    PubMed     Abstract available



  60. Correction: In the Clinic: Atrial Fibrillation.
    Ann Intern Med. 2017;166:920.
    PubMed    


  61. KRUGER P, Eikelboom J
    Resuming warfarin after intracranial hemorrhage in patients with AF was linked to reduced mortality.
    Ann Intern Med. 2017;166:JC70.
    PubMed    


    March 2017
  62. MEHTA SR
    After PCI with stents for AF, adding rivaroxaban vs warfarin to antiplatelet drugs reduced bleeding.
    Ann Intern Med. 2017;166:JC29.
    PubMed    


  63. BATES ER
    Review: In AF, direct oral anticoagulants reduce all-cause and vascular mortality compared with warfarin.
    Ann Intern Med. 2017;166:JC28.
    PubMed    


  64. MARTINEZ AM, Sanchez RC, Lacunza-Ruiz J, Ayala JM, et al
    Acute Myocardial Infarction Masked by Brugada Syndrome: A Case Report.
    Ann Intern Med. 2017;166:449-450.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Arrhythmias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: